When Off-Label Becomes Official: The Lytenava Approval and What It Means for the Retina Market

For more than two decades, retina specialists across the United States have been doing something technically irregular but practically indispensable: injecting bevacizumab, a cancer drug sold as Avastin, directly into the eyes of patients with wet age-related macular degeneration. The drug was never approved for this purpose. It was compounded in pharmacies, repackaged from intravenous vials, and administered off-label at a fraction of the cost of purpose-built alternatives. Millions of patients received it. It worked. And the FDA looked the other way.

That long-standing arrangement changed on July 24, 2026, when the FDA approved Lytenava (bevacizumab-vikg) from Outlook Therapeutics as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of neovascular, or wet, AMD. After three complete response letters, a formal dispute resolution process, and years of regulatory back-and-forth, the agency finally concluded that substantial evidence of effectiveness had been established. The approval was not a surprise to the retina community. It was, in many ways, a formality. But formalities in drug regulation carry enormous consequences.

The Off-Label Paradox

The story of bevacizumab in ophthalmology is one of the most striking examples of off-label medicine becoming de facto standard of care. Avastin, approved by the FDA in 2004 for colorectal cancer, was quickly recognized by retina specialists as a potent anti-VEGF agent that could suppress the abnormal blood vessel growth driving wet AMD. Compounding pharmacies began repackaging it into small ophthalmic doses, and the practice spread rapidly. Studies, including the landmark CATT trial funded by the National Eye Institute, confirmed that compounded bevacizumab was clinically comparable to Lucentis, a purpose-built anti-VEGF therapy priced at roughly $2,000 per injection. Compounded bevacizumab cost around $50 to $100 per dose.

The price differential was not incidental. It shaped prescribing patterns, insurance coverage decisions, and the economics of retinal care for an entire generation of patients. Wet AMD is a chronic, progressive disease requiring repeated injections over many years. The cumulative cost difference between compounded bevacizumab and branded alternatives runs into tens of thousands of dollars per patient. For Medicare, which covers the majority of wet AMD patients given the disease's prevalence in older adults, the savings were substantial enough that the program actively encouraged its use.

What the Approval Actually Changes

Outlook Therapeutics has positioned Lytenava as a purpose-built, FDA-regulated alternative to the compounded preparations that have dominated the market. The company argues, with some justification, that compounded bevacizumab lacks the manufacturing consistency, validated labeling, and pharmacovigilance infrastructure that a formally approved product provides. Lytenava is produced in the United States under FDA oversight, with approved labeling and ongoing safety monitoring. These are not trivial distinctions in a field where contamination events at compounding pharmacies have caused serious harm in the past.

The approval also comes with 12 years of reference product exclusivity under the Biologics Price Competition and Innovation Act, a provision that will prevent biosimilar competition for over a decade. That exclusivity window is the commercial foundation on which Outlook intends to build a business in the approximately $8.5 billion US retina market. The company has not yet disclosed its pricing strategy, but the market will be watching closely. If Lytenava is priced anywhere near the branded anti-VEGF therapies it competes with, the economic case for switching from compounded bevacizumab will be difficult to make for cost-conscious payers and patients.

The Pricing Tension Ahead

This is where the approval becomes genuinely complicated. The retina community has operated for years on the implicit understanding that compounded bevacizumab, while technically off-label, is clinically acceptable and economically rational. Payers have built formularies around it. Physicians have built practices around it. Patients have built treatment plans around it. The arrival of an FDA-approved version does not automatically displace that ecosystem, particularly if the approved version carries a price tag that makes the off-label alternative look even more attractive by comparison.

There is also a regulatory dimension worth watching. The FDA's approval of Lytenava does not make compounded bevacizumab illegal, but it does change the regulatory calculus. Under FDA rules, compounding of a drug that is essentially a copy of an approved product faces higher scrutiny. Whether the agency will move to restrict compounded bevacizumab in light of the Lytenava approval remains an open question, and one with significant implications for patient access and healthcare costs.

A Broader Lesson for Drug Development

The Lytenava story is also a reminder of how unusual the path to approval can be when a drug has already achieved widespread clinical adoption before formal regulatory clearance. Outlook faced a genuinely difficult evidentiary challenge: demonstrating effectiveness for a drug that the medical community had already accepted as effective, to a regulator that had watched millions of patients receive it off-label for two decades. Three complete response letters suggest the FDA was not simply rubber-stamping the obvious. The agency required rigorous clinical evidence through the NORSE program before granting approval, and the formal dispute resolution process that ultimately unlocked the path forward was itself a signal of how contested the regulatory science remained.

For the retina market, the next chapter will be written in pricing negotiations, formulary decisions, and the quiet arithmetic of cost-effectiveness that governs how drugs actually reach patients. Lytenava has cleared the regulatory hurdle. The commercial one may prove harder.